| Literature DB >> 25624754 |
Tih-Shih Lee1, Shin Yi Quek1, Siau Juinn Alexa Goh1, Rachel Phillips2, Cuntai Guan3, Yin Bun Cheung4, Lei Feng5, Chuan Chu Wang3, Zheng Yang Chin3, Haihong Zhang3, Jimmy Lee6, Tze Pin Ng5, K Ranga Rama Krishnan1.
Abstract
BACKGROUND: There is growing evidence that cognitive training (CT) can improve the cognitive functioning of the elderly. CT may be influenced by cultural and linguistic factors, but research examining CT programs has mostly been conducted on Western populations. We have developed an innovative electroencephalography (EEG)-based brain-computer interface (BCI) CT program that has shown preliminary efficacy in improving cognition in 32 healthy English-speaking elderly adults in Singapore. In this second pilot trial, we examine the acceptability, safety, and preliminary efficacy of our BCI CT program in healthy Chinese-speaking Singaporean elderly.Entities:
Keywords: attention; cognitive training; memory; neuro-feedback
Mesh:
Year: 2015 PMID: 25624754 PMCID: PMC4296917 DOI: 10.2147/CIA.S73955
Source DB: PubMed Journal: Clin Interv Aging ISSN: 1176-9092 Impact factor: 4.458
Figure 1CONSORT flow diagram.
Abbreviations: BCI, brain–computer interface; ITT, intention-to-treat.
Descriptive summary of responses to all items in the usability and acceptability questionnaire
| Questionnaire item | Mean (SD) | Median (range) |
|---|---|---|
| 1. Overall, I am satisfied with how easy it is to use this device | 6.7 (0.7) | 7 (4–7) |
| 2. I feel comfortable using this device | 6.4 (0.7) | 7 (5–7) |
| 3. I enjoyed playing the game | 6.7 (0.7) | 7 (4–7) |
| 4. I think the device is useful in training my memory and attention | 6.6 (0.8) | 7 (4–7) |
| 5. I will recommend this device to my friends and family | 6.5 (0.8) | 7 (4–7) |
| 6. Overall, I am satisfied with the interface of the game | 6.6 (0.8) | 7 (3–7) |
| 7. Overall, I am satisfied with the whole system | 6.6 (0.7) | 7 (4–7) |
Abbreviation: SD, standard deviation.
Adverse event form
| Item on form | Response options |
|---|---|
| Adverse event | 1= fatigue, 2= seizures, 3= syncope/dizziness, 4= sweating, 5= nausea, 6= headache, 7= others |
| Status | 0= absent, 1= present, 2= NA |
| CTCAE grade | 1= grade 1 (mild), 2= grade 2 (moderate), 3= grade 3 (severe), 4= grade 4 (life-threatening), 5= grade 5 (death) |
| Date of onset | DD/MM/YYYY |
| Date stopped (if applicable) | DD/MM/YYYY |
| Outcome | 1= recovered/resolved, 2= recovered/resolved with sequelae, 3= not recovered/not resolved, 4= fatal |
| Relationship | 1= none, 2= unlikely, 3= possible, 4= probable, 5= definite, 6= unknown, 7= NA |
| Action taken with study treatment | 1= none, 2= discontinued, 3= interrupted, 4= modified, 5= interrupted and modified, 6= not applicable |
| Medication used to treat this adverse event? | Y/N |
| Serious adverse event? | Y/N |
Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events; NA, not applicable; Y, yes; N, no; DD, day; MM, month; YYYY, year.
AEs reported and their characteristics
| Number of subjects (N=33) | Number of events | |
|---|---|---|
| Participants who ever experienced any AE | 10 (30.3) | 16 |
| Type of AE reported | ||
| Fatigue | 3 (9.1) | 3 |
| Headache | 4 (12.1) | 5 |
| Others | 2 (6.1) | 3 |
| Syncope/dizziness | 4 (12.1) | 5 |
| Severity, n (%) | ||
| Mild | 10 (30.3) | 15 |
| Moderate | 1 (3.0) | 1 |
| Relationship, n (%) | ||
| None | 1 (3.0) | 1 |
| Unlikely | 3 (9.1) | 6 |
| Possible | 5 (15.2) | 5 |
| Probable | 2 (6.1) | 3 |
| Unknown | 1 (3.0) | 1 |
| Medication used to treat this AE?, n (%) | ||
| No | 10 (30.3) | 16 |
| Outcome, n (%) | ||
| Recovered/resolved | 9 (27.3) | 15 |
| Not recovered/not resolved | 1 (3.0) | 1 |
| Action taken to study treatment, n (%) | ||
| None | 9 (27.3) | 15 |
| Interrupted | 1 (3.0) | 1 |
Note:
The three events reported were: “discomfort in the head but not headache” from one subject, and two reports of “eye pain, tearing” from another subject.
Abbreviation: AE, adverse event.
A comparison of change in RBANS domain and total scale index scores between Weeks 1 and 8 for the intervention and waitlist control arms
| Change in RBANS scores between Weeks 1 and 8 | Intervention | Waitlist | Median difference | |
|---|---|---|---|---|
| Immediate memory | ||||
| Mean (SD) | 5.7 (14.3) | −2.3 (15.9) | ||
| Median (range) | 3.5 (−22 to 29) | 0.0 (−32 to 26) | 0.129 | 7.0 (−3.0, 20.0) |
| Visuospatial/constructional | ||||
| Mean (SD) | 4.8 (12.9) | −1.3 (10.4) | ||
| Median (range) | 5.0 (−17 to 44) | 0.0 (−27 to 17) | 0.082 | 6.0 (0.0, 11.0) |
| Language | ||||
| Mean (SD) | 0.3 (16.2) | −1.4 (16.1) | ||
| Median (range) | −1.0 (−24 to 36) | 0.0 (−39 to 25) | 1.000 | 0.0 (−10.0, 11.0) |
| Attention | ||||
| Mean (SD) | 4.1 (10.2) | −0.5 (7.2) | ||
| Median (range) | 3.0 (−9 to 34) | 0.0 (−10 to 21) | 0.127 | −4.0 (−10.0, 1.0) |
| Delayed memory | ||||
| Mean (SD) | 3.0 (9.9) | −6.4 (11.5) | ||
| Median (range) | 0.0 (−19 to 24) | −2.5 (−24 to 9) | 0.042 | 8.0 (0.0, 17.0) |
| RBANS total scale index score | ||||
| Mean (SD) | 5.5 (11.8) | −3.5 (8.8) | ||
| Median (range) | 0.5 (−10 to 29) | −1.0 (−20 to 13) | 0.042 | 8.0 (0.0, 16.0) |
Notes:
P-value from the Mann–Whitney U-test
Hodges–Lehmann estimation and its associated 95% CI.
Abbreviations: CI, confidence interval; RBANS, Repeatable Battery for the Assessment of Neuropsychological Status; SD, standard deviation.
Changes in RBANS domain and total scale index scores between pre- and post-intervention, pooling data from the intervention and waitlist control groups
| Change in RBANS scores between Weeks 1 and 8 | Summary statistics (n=36) | |
|---|---|---|
| Immediate memory | ||
| Mean (SD) | 4.1 (16.0) | |
| Median (range) | 1.5 (−23 to 39) | 0.126 |
| Visuospatial/constructional | ||
| Mean (SD) | 1.7 (11.3) | |
| Median (range) | 0.0 (−19 to 44) | 0.462 |
| Language | ||
| Mean (SD) | 0.22 (16.6) | |
| Median (range) | 0.0 (−45 to 36) | 0.984 |
| Attention | ||
| Mean (SD) | 4.1 (9.3) | |
| Median (range) | 1.5 (−12 to 34) | 0.008 |
| Delayed memory | ||
| Mean (SD) | 3.1 (9.1) | |
| Median (range) | 0.0 (−19 to 24) | 0.039 |
| RBANS total scale index score | ||
| Mean (SD) | 4.1 (10.4) | |
| Median (range) | 1.0 (−15 to 29) | 0.039 |
Note:
P-value from Wilcoxon signed-rank test.
Abbreviations: RBANS, Repeatable Battery for the Assessment of Neuropsychological Status; SD, standard deviation.